



ORIGINAL ARTICLE

The frequency of lung cancer in patients with pulmonary hamartomas: An evaluation of clinical, radiological, and pathological features and follow-up data of 96 patients with pulmonary hamartomas



G.H. Ekinci^{a,*}, O. Hacıömeroğlu^a, A. Ersev^b, L. Alpay^c, H. Özgen^a, A. Yılmaz^a

^a Department of Pulmonology, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Maltepe, İstanbul, Turkey

^b Department of Pathology, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Maltepe, İstanbul, Turkey

^c Department of Thoracic Surgery, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Maltepe, İstanbul, Turkey

Received 19 October 2016; accepted 25 April 2017

Available online 1 June 2017

KEYWORDS

Hamartoma;
Lung neoplasms;
Diagnosis

Abstract

Purpose: To investigate the frequency of lung cancer in patients with pulmonary hamartomas and to evaluate clinical, radiological, and pathological characteristics of pulmonary hamartomas.

Basic procedures: We reviewed pathology records of pulmonary hamartomas diagnosed between 2003 and 2014. Medical records and the hospital electronic database were also reviewed for each patient to obtain clinical, radiological, and pathological characteristics of pulmonary hamartomas and accompanying malignancies.

Main findings: Ninety-six patients with pulmonary hamartomas were identified. There were 26 females (27%) and 70 males (73%), with a mean age of 56.2 years (range 22–87 years). Malignancies were detected in 23 patients (24%), which developed previously in five patients (1 synchronous, 4 metachronous lesions), and concomitantly in 18 patients (with origin from the lung in 17 patients and from the pleura in 1 patient).

* Corresponding author.

E-mail address: gulbanuh@hotmail.com (G.H. Ekinci).

Principal conclusions Our results show that patients with pulmonary hamartomas may have coexisting lung malignancies.

© 2017 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The term hamartoma was first introduced by Albrecht in 1904 to describe lesions that contain an abnormal mixture of tissue elements or an abnormal proportion of a single element, normally present in an organ. While hamartoma was initially considered a developmental malformation, it is now classified as a true benign mesenchymal tumor, consisting of cartilage, fat, fibromyxoid connective tissue, smooth muscle, and bone.^{1,2} Hamartomas can occur in any organ or region. Pulmonary hamartoma is the most common benign tumor of the lung, accounting for 3% of all lung tumors.³ Its incidence was found as 0.025% and 0.32% in two large autopsy-based studies.⁴

There have been many reports suggesting an association between hamartoma and malignancy,^{5–10} and the likelihood of its malignant transformation to carcinoma or sarcoma.^{5–7} The risk for lung cancer in pulmonary hamartoma patients was estimated to be 6.3 times as high as that expected for the general population after adjustment for age, sex, and ethnicity.⁸ Additionally, patients with pulmonary hamartomas can develop synchronous or metachronous lung cancers.^{9,10} The aim of this study was to investigate the frequency of lung cancer in patients with pulmonary hamartomas and to evaluate clinical, radiological, and pathological characteristics of pulmonary hamartomas accompanied by lung cancer.

Materials and methods

This retrospective study was conducted at Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey, after being approved by the scientific committee of our institute. A comprehensive review of pathology records was made for pulmonary hamartomas diagnosed between 2003 and 2014, which yielded a total of 97 patients. All histologic slides were re-examined by a pathologist experienced in thoracic pathology to re-confirm the diagnosis of pulmonary hamartomas. One patient whose diagnosis could not be confirmed was excluded from the study. Thus, the study included 96 patients with pulmonary hamartomas.

Medical records and the hospital electronic database were reviewed for each patient and a standardized data-collection form was used to collect the following information: gender, age at diagnosis, history of smoking, medical history, the presence of malignancies (previous, concurrent), symptoms, radiological and imaging findings, location and size of hamartomas, findings of preoperative diagnostic investigations, duration between diagnosis of malignancy and pulmonary hamartoma, malignancy

staging, treatment modalities, histologic features, duration of follow-up, and outcome. Follow-up information included data till January 2015.

Results

Of 96 patients with pulmonary hamartomas, 26 (27%) were females and 70 (73%) were males, with a female-to-male ratio of 1:2.7. The mean age was 56.2 years (range 22–87 years). Only one patient was younger than 30 years. Sixty-one patients (63.5%) were between 30 and 60 years and 34 patients (35.4%) were older than 60 years. With respect to smoking, 62 patients (64.6%) were smokers (mean 41.2 pack-years), and 34 (35.4%) had never smoked.

At presentation, 27 patients (28%) were symptom-free, while the remaining 69 patients (72%) had pulmonary and/or constitutional symptoms. The presenting symptoms were cough ($n=27$), chest pain ($n=26$), dyspnea ($n=23$), hemoptysis ($n=10$), fever ($n=7$), sputum production ($n=5$), and constitutional symptoms ($n=7$). The duration of symptoms ranged from 4 days to 1 year.

Chest X-ray examination was performed in all patients, which showed abnormal findings in all but three patients. Eighteen patients also had findings associated with concomitant malignancies. All patients underwent computed tomography and bronchoscopic examinations. The diagnoses of pulmonary hamartomas were established via bronchoscopic biopsies in 19 patients, computed tomography-guided transthoracic fine-needle aspiration in three patients, and surgical biopsies in 74 patients. A single hamartoma was found in 93 patients (97%) which was located in the right lung in 54 patients (58%) and in the left lung in 39 patients (42%). Three patients (3%) had multiple hamartomas, with two patients having two hamartomas in the right and left lungs, and one patient having three hamartomas in the same lobe. The hamartomas were parenchymal in 72 patients (75%) and endobronchial in 24 patients (25%). The mean diameter of pulmonary hamartomas was 22.2 mm (range 3 mm–100 mm).

There was no evidence for malignancy in 73 patients (76%) including 50 males and 23 females, with a mean age of 53.9 years (range 22–76 years). Data on these patients are summarized in Table 1. Of these, 44 patients (60.3%) were smokers and 50 patients (68.5%) were symptomatic at presentation. The most common radiological pattern was a solitary pulmonary nodule, followed by a solitary mass. Seventy patients (95.9%) had a single hamartoma and three patients (4.1%) had multiple hamartomas. The hamartomas were parenchymal in 52 patients (71.2%) and endobronchial in 21 patients (28.8%). The diameter of pulmonary hamartomas ranged from 6 mm to 100 mm (mean 25.4 mm). ¹⁸Fluoro-deoxyglucose positron emission

Table 1 Characteristics of the hamartoma patients without any malignancy.

Features	n	%
No. of patients	73	76
Male	50	68.5
Female	23	31.5
Age		
<30 years	1	1.5
30–60 years	51	69.9
>60 years	21	28.8
Mean age (range) years	53.9 (22–76)	
Smoking		
Present	44	60.3
Absent	29	39.7
Mean duration	36.5 (10–90) pack-year	
Radiological findings		
Normal	3	4.1
Nodule	44	60.3
Mass	12	16.4
Consolidation	6	8.2
Multiple pulmonary nodules	3	4.1
Atelectasis	3	4.1
Nodule and atelectasis	1	1.4
Mass and atelectasis	1	1.4
Locations		
The right upper lobe	13	17.8
The right middle lobe	7	9.6
The right lower lobe	20	27.4
The left upper lobe	8	11
The left lower lobe	20	27.4
The left main bronchi	3	4.1
Bilateral	2	2.7

tomography-computed tomography (FDG PET-CT) was performed in 28 patients. Maximum standard uptake values (SUV_{max}) ranged from ametabolic to 9.7. Of 73 patients without malignancies, four patients rejected treatment. Endobronchial treatment was performed in nine patients, including rigid forceps ($n=3$), cryotherapy ($n=3$), electrocautery ($n=2$), and argon plasma coagulation ($n=1$). Sixty patients underwent surgical treatment which included wedge resection ($n=26$), extirpation ($n=14$), lobectomy ($n=11$), enucleation ($n=4$), bronchotomy ($n=3$), and segmentectomy ($n=2$). Sixty-five patients (89%) were followed for a mean duration of 67.1 months (range 4–131 months). None of these patients had evidence of recurrence or developed subsequent malignancies.

Twenty-three patients (24%) had malignancies, which occurred previously in five patients (Table 2), and concomitantly in 18 patients (Table 3). The patients with previous malignancies ranged in age from 44 to 73 years. While four male patients were smokers, one female patient had never smoked. Two patients (Case 1 and 2) were asymptomatic. The lesions were metachronous in four patients and synchronous in one patient. Radiologically, four patients had solitary pulmonary nodules with no findings associated with

malignancy. One patient had a metastatic pulmonary nodule from renal cell carcinoma. FDG PET-CT was performed in four patients. In the patient with metastatic renal cell carcinoma, the SUV_{max} was 7.4 for the malignant lesion and ametabolic for the pulmonary hamartoma. These values were ametabolic, 1.8, and 3.4 in the remaining three patients, respectively.

Of the 18 patients with concomitant malignancies, 16 were males and two were females, with a mean age of 63 years (range 35–87 years). Fourteen patients (77.8%) were smokers, with a mean duration of 57.1 pack-years (range 20–150 pack-years). Only one patient was symptom-free at presentation. Malignancies originated from the lung in 17 patients and from the pleura in one patient. Coexistence of a hamartoma and malignancy was diagnosed preoperatively in two patients. Malignancies were diagnosed before surgery and hamartomas after surgery in 10 patients. Preoperatively, five patients had no diagnoses of hamartoma or malignancy. One patient had the diagnosis of hamartoma before surgery, after which malignancy was diagnosed. Pulmonary hamartomas and malignancies were located in the ipsilateral lung in 12/17 patients and in the same lobe in four patients. FDG PET-CT was performed in 14 patients, all of whom had ametabolic SUV_{max} values for hamartomas. SUV_{max} values for malignancies ranged from 2.4 to 35.5, with a mean value of 14.4.

Discussion

Benign tumors of the lung are very rare, with pulmonary hamartoma being the most common.² It accounts for 3% of all lung tumors and 77% of benign lung tumors.^{3,11} Pulmonary hamartomas can be parenchymal or endobronchial in location. The latter accounts for only 1–19.5% of pulmonary hamartomas.⁴ At presentation, most patients are free of symptoms, and pulmonary hamartomas are detected incidentally on chest X-rays obtained for other reasons. The typical radiographic feature is a coin lesion in the periphery of the lung. On rare occasions, pulmonary hamartomas can present as multiple nodules.^{10,12}

Pulmonary hamartomas are generally considered to be benign neoplasms. However, there have been several reports on the association between hamartomas and malignancies,^{5–10,13,14} and the likelihood of malignant transformation to carcinoma or sarcoma.^{5–7} There are cases of adenocarcinoma, squamous cell carcinoma, and sarcoma arising from pulmonary hamartomas.^{7,13,14} Lee et al.¹⁴ reported a case of squamous cell carcinoma originating from a pulmonary hamartoma. Pulmonary hamartomas may also coexist with metastatic lung tumors. A literature review reported 10 cases of coexisting hamartomas and metastatic lung tumors.¹⁵ In addition, patients with pulmonary hamartomas can have synchronous or metachronous extrathoracic malignancies.^{16,17} The risk for lung cancer in pulmonary hamartoma patients was estimated to be 6.3 and 6.66 times as high as the age-sex-ethnicity adjusted rate expected for the general population.^{8,9} Pulmonary hamartomas can frequently be diagnosed in patients undergoing resection for primary lung cancers.^{18,19} Smith et al.¹⁸ found the prevalence of hamartoma to be 12% in patients undergoing resection for suspected lung

Table 2 Features of the hamartoma patients with previous malignancies.

Case	Age	Sex ^a	Malignancy			Pulmonary hamartoma				Follow-up (month)	Survival
			Tumor	Treatment	Duration (month)	Location ^b	Lesion	Diameter	Treatment		
1	44	F	Papillary thyroid carcinoma	Thyroidectomy	12	RLL	Nodule	10 mm	Wedge resection	84	Alive
2	48	M	Testicular Leydig cell tumor	Orchiectomy	4	RLL	Nodule	25 mm	Wedge resection	23	Alive
3	65	M	Renal cell carcinoma	Nephrectomy	24	LLL	Nodule	10 mm	Wedge resection	62	Dead
4	58	M	Larynx carcinoma	Laryngectomy	36	LUL	Nodule	4 mm	Lobectomy	14	Dead
5	73	M	Larynx carcinoma	Laryngectomy	288	LLL	Nodule	15 mm	Wedge resection	101	Alive

^a F: female, M: male.^b LLL: left lower lobe, LUL: left upper lobe, RLL: right lower lobe.**Table 3a** The clinical, radiological, and pathological features of the hamartoma patients with concomitant malignancies.

Case	Age	Sex ^a	Smoking		Radiological findings			Malignancy		
			Smoking status	Pack-years	Hamartoma	Malignancy	Hamartoma size (mm)	Site	Tumor type	
1	76	M	Smoker	80	Nodule	Nodule	8	Lung	Squamous	
2	87	M	Smoker	120	Mass	Nodule	40	Lung	Squamous	
3	62	M	Smoker	55	Nodule	Mass	20	Lung	Adenocarcinoma	
4	59	M	Smoker	30	Nodule	Atelectasis	8	Lung	Adenocarcinoma	
5	52	F	Non-smoker	-	Nodule	Nodule	3	Lung	Adenocarcinoma	
6	64	M	Smoker	60	Nodule	Nodule	8	Lung	Adenocarcinoma	
7	62	M	Smoker	50	Nodule	Mass	15	Lung	Squamous	
8	52	F	Smoker	25	Nodule	Nodule	20	Lung	Adenocarcinoma	
9	59	M	Non-smoker	-	Nodule	Nodule	29	Lung	Adenocarcinoma	
10	64	M	Smoker	150	Nodule	Mass	20	Lung	Squamous	
11	70	M	Smoker	40	Nodule	Mass	10	Lung	Adenocarcinoma	
12	54	M	Smoker	40	Nodule	Nodule	8	Lung	Adenocarcinoma	
13	60	M	Smoker	50	Nodule	Mass and atelectasis	6	Lung	Squamous	
14	78	M	Non-smoker	-	Nodule	Mass	5	Lung	Adenocarcinoma	
15	35	M	Smoker	20	Nodule	Nodule	15	Lung	Typical carcinoid	
16	71	M	Smoker	40	Nodule	Pleural effusion	12	Lung	Adenocarcinoma	
17	61	M	Smoker	40	Nodule	Mass	7	Lung	Squamous	
18	67	M	Non-smoker	-	Nodule	Pleural effusion	5	Pleura	Mixed Mesothelioma	

^a F: female, M: male.

cancers. Similarly, many patients with resected pulmonary hamartomas were found to have simultaneous, synchronous or metachronous lung cancers.^{2,9,10,20-22} Kawano et al.²⁰ reported simultaneous primary lung cancers in 25% of patients with resected pulmonary hamartomas. Van den Bosch et al.¹⁰ found bronchial carcinomas in 11 of 154 patients with pulmonary hamartomas, synchronous in six and metachronous in five. It is clear that there is a high incidence of malignancies in cases with pulmonary hamartomas; however, the question as to whether

these malignancies are coincidental entities or associated with malignant growth in existing hamartomas remains uncertain.^{2,7-10,20} Ruchita et al.⁷ found no pathophysiologic association between pulmonary hamartomas and lung cancer development. A previous report suggested an etiologic association between hamartomas and malignancies.⁸ Smoking and environmental carcinogenic factors have also been implicated as important risk factors for the development of lung carcinoma in patients with pulmonary hamartomas.^{2,9}

Table 3b Stage, treatment, and outcome of the patients with concomitant malignancies.

Case	Hamartoma type	Location ^a		Stage		Treatment modality		Follow-up	Survival
		Hamartoma	Malignancy	Malignancy	Hamartoma	Malignancy	Malignancy		
1	Endobronchial	RUL	LUL	T2aN0M0	Rigid forceps	Lobectomy		36 months	Dead
2	Parenchymal	LUL	LLL	T1bN0M0		Pneumonectomy + MLND ^b		11 months	Dead
3	Parenchymal	LLL	LUL	T2aN1M0	Extirpation	Lobectomy		91 months	Dead
4	Parenchymal	RUL	LUL	T2aN2M0	Extirpation	Pneumonectomy + MLND		35 months	Dead
5	Parenchymal	RUL	RLL	T1aN2M0	Wedge resection	Lobectomy + MLND		38 months	Dead
6	Parenchymal	LUL	LUL	T1aN0M0		Lobectomy + MLND		101 months	Dead
7	Parenchymal	RUL	RUL	T1bN0M0	Wedge resection	Lobectomy + MLND		31 months	Alive
8	Parenchymal	RML	RLL	T4N0M0		Bilobectomy inferior		30 months	Alive
9	Parenchymal	LLL	RUL	T1bN0M0	Extirpation	Lobectomy + MLND		63 months	Alive
10	Parenchymal	RML	LLL	T3N0M0	Wedge resection	Lobectomy + MLND		39 months	Dead
11	Parenchymal	RLL	RUL	T3N0M0	Wedge resection	Lobectomy + MLND		45 months	Alive
12	Parenchymal	RLL	RUL	T1bN2M0	Wedge resection	Lobectomy + MLND		18 months	Alive
13	Endobronchial	RUL	LLL	T2aN0M0		No		1 month	Dead
14	Parenchymal	LLL	LLL	T4N2M0		Pneumonectomy + MLND		1 month	Dead
15	Parenchymal	RLL	RUL	T2aN0M0	Wedge resection	Sleeve resection		2 months	Alive
16	Endobronchial	Left Main Bronchi	LLL	T1bN0M1b	Bronchotomy	Chemotherapy		14 months	Alive
17	Parenchymal	RUL	RUL	T3N0M0		Lobectomy + chest wall resection		3 months	Alive
18	Parenchymal	RLL	Right pleura	T2N0M0	Wedge resection	Pleurectomy		11 months	Dead

^a LLL: left lower lobe, LUL: left upper lobe, RML: right middle lobe, RLL: right lower lobe, RUL: right upper lobe.

^b MLND: multiple lymph node dissection.

We found concomitant malignancies in 23 patients (24%). Five of these had previous lesions. Radiologically, hamartomas in these patients presented as a solitary pulmonary nodule or multiple pulmonary nodules. When solitary or multiple pulmonary nodules are detected in patients with a known malignancy, authors tend to regard every nodule as a metastasis. However, these nodules can be associated with synchronous or metachronous primary lung cancers or benign lesions such as hamartoma, as seen in our cases.^{2,10,15,23} Malignancy was concomitant in 18 patients. Radiological examination showed multiple pulmonary lesions in all these patients. Most patients had a preoperative diagnosis of a malignant tumor and thus were evaluated for satellite lesions. When a satellite lesion is detected in a patient with known malignancy, we tend to consider it a metastatic lung tumor. However, these satellite lesions can be associated with simultaneous primary lung cancers or benign lesions accompanying malignant tumors.^{18,19,23} A previous report noted that the prevalence of a benign disease was 9% in patients undergoing resection for suspected lung cancers, with pulmonary hamartomas accounting for 9% of satellite benign lesions.¹⁸ When satellite nodules or masses are identified in patients with pulmonary hamartomas, we tend to consider them multiple pulmonary hamartomas, as was the case in our three patients. However, these lesions can be associated with other lung pathologies accompanying pulmonary hamartomas, including synchronous lung cancers, metastatic lung tumors, and benign pulmonary diseases such as tuberculosis.^{9,15,20} On the other hand, patients with pulmonary hamartomas may develop subsequent pulmonary lesions, which may be recurrences of pulmonary hamartomas or subsequent malignancies.^{2,21} In the presence of a malignancy or hamartoma, it is important to make diagnostic investigations for the differential diagnosis of each pulmonary nodule.^{15,23}

Conclusions

Hamartomas are common and linked to the same exposures and risk factors as those for lung cancer, larynx cancer, and others. The majority of hamartomas are parenchymal and appear as a solitary pulmonary nodule on a roentgenogram. On rare occasions, pulmonary hamartomas can present as multiple nodules. Hamartomas may be accompanied by lung malignancies. The possibility of coexisting benign lesions such as hamartomas should be considered when solitary or multiple pulmonary lesions are found in patients with primary lung cancers or metastatic lung tumors.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

None.

References

- Rai SP, Patil AP, Saxena P, Kaur A. Laser resection of endobronchial hamartoma via fiberoptic bronchoscopy. *Lung India*. 2010;27:170–2.
- Gjever JA, Myers JL, Prakash UB. Pulmonary hamartomas. *Mayo Clin Proc*. 1996;71:14–20.
- Guo W, Zhao YP, Jiang YG, Wang RW, Ma Z. Surgical treatment and outcome of pulmonary hamartoma: a retrospective study of 20-year experience. *J Exp Clin Cancer Res*. 2008;27:8, <http://dx.doi.org/10.1186/1756-9966-27-8>.
- Lien YC, Hsu HS, Li WY, Wu YC, Hsu WH, Wang LS, et al. Pulmonary hamartoma. *J Chin Med Assoc*. 2004;67:21–6.
- Choi N, Ko ES. Invasive ductal carcinoma in a mammary hamartoma: case report and review of the literature. *Korean J Radiol*. 2010;11:687–91.
- Poulsen JT, Jacobsen M, Francis D. Probable malignant transformation of a pulmonary hamartoma. *Thorax*. 1979;34:557–8.
- Ruchita T, Amajit B, Divyesh M, Raje N, Ashim D. Pulmonary hamartoma, a rare benign tumour of the lung-case series. *Asian J Med Sci*. 2014;5:112–5, <http://dx.doi.org/10.3126/ajms.v5i3.9243>.
- Karasik A, Modan M, Jacob CO, Lieberman Y. Increased risk of lung cancer in patients with chondromatous hamartoma. *J Thorac Cardiovasc Surg*. 1980;80:217–20.
- Ribet M, Jaillard-Thery S, Nuttens MC. Pulmonary hamartoma and malignancy. *J Thorac Cardiovasc Surg*. 1994;107:611–4.
- Van den Bosch JM, Wagenaar SS, Corrin B, Elbers JR, Knaepen PJ, Westermann CJ. Mesenchymoma of the lung (so called hamartoma): a review of 154 parenchymal and endobronchial cases. *Thorax*. 1987;42:790–3.
- Arrigoni MG, Woolner LB, Bernatz PE, Miller WE, Fontana RS. Benign tumors of the lung. A ten-year surgical experience. *J Thorac Cardiovasc Surg*. 1970;60:589–99.
- Lazovic B, Jakovic R, Dubajic S, Gataric Z. Pulmonary hamartoma-case report and review of literature. *Arch Oncol*. 2011;19:37–8, <http://dx.doi.org/10.2298/AOO1102037L>.
- Zeybek A, Sarper A, Kalemci S, Oz N, Erdogan A, Ozbudak IH, et al. Benign lung tumors and their association with malignant tumors. *Acta Med Mediterranea*. 2013;29:545–50.
- Lee BJ, Kim HR, Cheon GJ, Koh JS, Kim CH, Lee JC. Squamous cell carcinoma arising from pulmonary hamartoma. *Clin Nucl Med*. 2011;36:130–1.
- Kanno R, Yonechi A, Higuchi M, Suzuki H, Ohishi A. Concomitant metastatic lung tumor and hamartoma. *Fukushima J Med Sci*. 2014;60:129–32.
- Jindal A, Madan K, Nijhawan R, Singh N. Incidental pathologically proven pulmonary hamartoma in a patient with carcinoma tongue. *BMJ Case Rep*. 2013, <http://dx.doi.org/10.1136/bcr-2013-008942>, pii:bcr2013008942.
- Silva VA, Kataguiri P, Trufelli DC, Matos LL, Neves-Pereira JC, Campos JR. Pulmonary hamartoma as a differential

- diagnosis of breast cancer metastasis: case report. *J Bras Pneumol.* 2007;33:738–42.
- 18. Smith MA, Battafarano RJ, Meyers BF, Zoole JB, Cooper JD, Patterson GA. Prevalence of benign disease in patients undergoing resection for suspected lung cancer. *Ann Thorac Surg.* 2006;81:1824–9.
 - 19. Cahan WG, Shah JP, Castro EB. Benign solitary lung lesions in patients with cancer. *Ann Surg.* 1978;187:241–4.
 - 20. Kawano R, Sato F, Tagawa K, Yokota F, Ikeda S, Hata E. Clinicopathological study of patients with coexistence of pulmonary hamartoma and primary lung cancer. *J Jpn Assoc Chest Surg.* 2007;21:526–30.
 - 21. Fudge TL, Ochsner JL, Mills NL. Clinical spectrum of pulmonary hamartomas. *Ann Thorac Surg.* 1980;30:36–9.
 - 22. Salminen US. Pulmonary hamartoma. A clinical study of 77 cases in a 21-year period and review of literature. *Eur J Cardiothorac Surg.* 1990;4:15–8.
 - 23. Önen A, Şanlı A, Karapolat S, Karacam V, Kargı A. Pulmonary hamartoma and squamous cell carcinoma: a very rare coexistence. *Turkish J Thorac Cardiovasc Surg.* 2007;15:311–3.